Edgewise Therapeutics, Inc. ($EWTX)
Filing Information
| Accession Number | 0001853109-26-000001 |
|---|---|
| Form Type | 4 |
| Filing Date | Aug 14, 2026 |
| Document | View SEC Filing |
Transactions
10
Total Shares
181,662
Total Value
$223,424.05
P&L
+inf% (+$6,625,500.00)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer | Common Stock | โ | Aug 12, 2026 | Exercise/Conversion | 5,781 | $0.00 | $0.00 | 29,426 | Direct | โ | View Details | |
Chief Business Officer | Common Stock | โ | Aug 12, 2026 | Exercise/Conversion | 7,500 | $0.00 | $0.00 | 36,926 | Direct | โ | View Details | |
Chief Business Officer | Common Stock | โ | Aug 12, 2026 | Sale | 2,171 | $43.79 | $95,075.47 | 34,755 | Direct | โ | View Details | |
Chief Business Officer | Common Stock | โ | Aug 12, 2026 | Sale | 304 | $44.50 | $13,528.55 | 34,451 | Direct | โ | View Details | |
Chief Business Officer | Common Stock | โ | Aug 12, 2026 | Sale | 150 | $44.44 | $6,666.49 | 34,301 | Direct | โ | View Details | |
Chief Business Officer | Common Stock | โ | Aug 12, 2026 | Sale | 2,475 | $43.70 | $108,153.54 | 31,826 | Direct | โ | View Details | |
Chief Business Officer | Restricted Stock Units | Derivative | Aug 12, 2026 | Exercise/Conversion | 5,781 | $0.00 | $0.00 | 11,563 | Direct | โ | View Details | |
Chief Business Officer | Restricted Stock Units | Derivative | Aug 12, 2026 | Exercise/Conversion | 7,500 | $0.00 | $0.00 | 22,500 | Direct | โ | View Details | |
Chief Business Officer | Restricted Stock Units | Derivative | Aug 12, 2026 | Grant/Award | 50,000 | $0.00 | $0.00 | 50,000 | Direct | โ | View Details | |
Chief Business Officer | Stock Option (Right to Buy) | Derivative | Aug 12, 2026 | Grant/Award | 100,000 | $0.00 | $0.00 | 100,000 | Direct | โ | View Details |